Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 693

1.

Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis.

Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB.

Hepatology. 2002 Aug;36(2):410-7.

PMID:
12143050
2.

The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma.

Peng YC, Chan CS, Chen GH.

Hepatogastroenterology. 1999 Nov-Dec;46(30):3208-11.

PMID:
10626187
3.

Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.

Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ.

J Gastroenterol Hepatol. 2008 Oct;23(10):1541-8. doi: 10.1111/j.1440-1746.2008.05395.x. Epub 2008 Apr 19.

PMID:
18422961
4.

Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients.

Cedrone A, Covino M, Caturelli E, Pompili M, Lorenzelli G, Villani MR, Valle D, Sperandeo M, Rapaccini GL, Gasbarrini G.

Hepatogastroenterology. 2000 Nov-Dec;47(36):1654-8.

PMID:
11149026
5.
6.

Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies.

Murugavel KG, Mathews S, Jayanthi V, Shankar EM, Hari R, Surendran R, Vengatesan A, Raghuram K, Rajasambandam P, Murali A, Srinivas U, Palaniswamy KR, Pugazhendhi T, Thyagarajan SP.

Int J Infect Dis. 2008 Nov;12(6):e71-6. doi: 10.1016/j.ijid.2008.04.010. Epub 2008 Jul 26.

7.

Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.

Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, Carroccio A, Sesti R, Tripi S, Montalto G.

Anticancer Res. 2003 Mar-Apr;23(2C):1747-53.

PMID:
12820452
8.

Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.

Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R.

Am J Gastroenterol. 2000 Apr;95(4):1036-40.

PMID:
10763956
9.

The predictive ability of serum alpha-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance.

Huo TI, Hsia CY, Chu CJ, Huang YH, Lui WY, Wu JC, Lee PC, Chi CW, Lee SD.

J Surg Oncol. 2007 Jun 15;95(8):645-51.

PMID:
17530668
10.

The value of serum tissue polypeptide specific antigen in the diagnosis of hepatocellular carcinoma.

Tu DG, Wang ST, Chang TT, Chiu NT, Yao WJ.

Cancer. 1999 Mar 1;85(5):1039-43.

PMID:
10091786
11.

Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis.

Sorvillo F, Mazziotti G, Carbone A, Morisco F, Cioffi M, Rotondi M, Stornaiuolo G, Amato G, Gaeta GB, Caporaso N, Carella C.

Clin Endocrinol (Oxf). 2003 Feb;58(2):207-12.

PMID:
12580937
12.

Assessment of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma in Middle Eastern patients.

Sanai FM, Sobki S, Bzeizi KI, Shaikh SA, Alswat K, Al-Hamoudi W, Almadi M, Al Saif F, Abdo AA.

Dig Dis Sci. 2010 Dec;55(12):3568-75. doi: 10.1007/s10620-010-1201-x. Epub 2010 Apr 16.

PMID:
20397051
13.

Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.

Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M.

Clin Gastroenterol Hepatol. 2009 Jan;7(1):104-13. doi: 10.1016/j.cgh.2008.08.041. Epub 2008 Sep 17.

PMID:
18849011
14.

Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.

Gadelhak NA, Gadelhak SA, El-Morsi DA, Abdelaziz MM, Abbas AT, El-Emshaty HM.

Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1417-24.

PMID:
19950803
15.
16.

Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.

Wu C, Wang Z, Liu L, Zhao P, Wang W, Yao D, Shi B, Lu J, Liao P, Yang Y, Zhu L.

J Gastroenterol Hepatol. 2009 Jan;24(1):55-62. doi: 10.1111/j.1440-1746.2008.05580.x. Epub 2008 Sep 24.

PMID:
18823443
17.

Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand.

Tangkijvanich P, Tosukhowong P, Bunyongyod P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y.

Southeast Asian J Trop Med Public Health. 1999 Mar;30(1):110-4.

PMID:
10695798
18.

Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis.

Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME.

Am J Gastroenterol. 2007 Oct;102(10):2196-205. Epub 2007 Jul 7.

PMID:
17617202
19.

Clinical evaluation of serum alpha-fetoprotein-IgM immune complexes on the diagnosis of primary hepatocellular carcinoma.

Jingting J, Changping W, Ning X, yibei Z, Jun W, Mei J, Bin X, Peter NE, Xueguan Z.

J Clin Lab Anal. 2009;23(4):213-8. doi: 10.1002/jcla.20321.

PMID:
19623644
20.

Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.

Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K.

Scand J Gastroenterol. 2008;43(7):849-56. doi: 10.1080/00365520801935459.

PMID:
18584524

Supplemental Content

Support Center